A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05509985
• Other study ID #: ASKG315-101
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: August 9, 2023
• Est. completion date: September 9, 2024

Study information

• Verified date: August 2022
• Source: AskGene Pharma, Inc.
• Contact: Chief Medical Officer
• Phone: 805-389-2956
• Email: barbara.hickingbottom[@]ask-gene.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent (Part 1) and in combination with pembrolizumab (Part 2) in patients with advanced solid tumors.

Description:

Each part of the study consists of 3 periods: screening (up to 28 days), treatment and follow-up. After an initial screening period, ASKG315 or ASKG315 combined with pembrolizumab will be administered once every 3 weeks by intravenous (IV) infusion. The Part 1 dose escalation consists of 6 planned escalation cohorts, with a starting dose of 3 mg. The Part 2 dose escalation consists of 4 planned escalation cohorts.

Part 2 of the study will begin enrolling after Part 1 has successfully and safely dosed all patients in the first two cohorts and followed these patients through the entire DLT period. The starting dose of Part 2 will be determined according to the safety and PK of ASKG315 in Part 1 of the study, but in no case will it exceed the highest dose already safely administered in Part 1 and confirmed as tolerable by the Safety Review Committee in Part 1.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: September 9, 2024
• Est. primary completion date: September 9, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent form.

2. Male or female = 18 years of age (at the time signed consent is obtained).

3. Histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.

4. Measurable disease, per RECIST v1.1.

5. ECOG Performance Status of = 2.

6. Life expectancy of =3 months, in the opinion of the Investigator.

7. Adequate organ function defined.

8. Fertile patients must be willing to use effective contraceptive measures (hormonal or barrier methods or abstinence, etc.) starting with the Screening visit through 90 days + 5 drug half-lives after the last dose of study treatment.

9. Negative serum pregnancy test for female patients within 7 days prior to the first dose of the study drug or documentation of lack of childbearing potential.

10. Willing and able to participate in the trial and comply with all trial requirements.

Exclusion Criteria:

Patients who meet any of the following criteria are not allowed to be enrolled:

1. Received any other investigational drug for treatment that is not commercially available within 4 weeks prior to Cycle 1 Day 1.

2. Received chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, or any other anti-tumor treatments within 4 weeks prior to Cycle 1 Day 1.

3. Had major organ surgery or significant trauma within 4 weeks prior to C1D1 or planning elective surgery during the study period.

4. Received systemic glucocorticoid or other immunosuppressant treatment within 14 days prior to C1D1.

5. Received immunomodulatory drugs, including but not limited to thymosin and interferon, within 14 days prior to C1D1.

6. Received a live attenuated vaccine within 4 weeks prior to C1D1.

7. Received IL-2 or IL-15 therapy within 12 weeks prior to C1D1.

8. History of hematologic stem cell transplant or solid organ transplant.

9. Adverse reactions to previous antitumor therapy have not recovered to CTCAE 5.0 grade = 1.

10. Cerebral parenchymal metastasis or meningeal metastasis with clinical symptoms.

11. Have an active infection that currently requires intravenous anti-infection therapy.

12. A history of human immunodeficiency virus (HIV) infection with a CD4+ T-cell count of =350 cells/µL at screening. HIV positive patients must be receiving adequate treatment.

13. If serological evidence of chronic hepatitis B virus infection (HBV), viral load below the limit of quantification at screening.

14. If serological evidence of hepatitis C virus infection (HCV), should have completed curative antiviral treatment and have HCV viral load below the limit of quantification at screening.

15. Current clinically significant interstitial lung disease.

16. History of serious cardiovascular or cerebrovascular diseases.

17. Active or recurrent autoimmune diseases.

18. History of Grade = 3 Immune-Related Adverse Events (irAE) or Grade = 2 immunotherapy-associated myocarditis associated with treatment with an immune checkpoint inhibitor.

19. Grade = 3 bleeding .

20. Symptomatic with uncontrolled ascites or pleural effusion.

21. History of a grade = 3 allergic reaction to protein drugs.

22. Known to have alcohol or drug dependence.

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Neoplasms

Intervention

Biological:
• ASKG315
Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.

Locations

Country	Name	City	State
Australia	The Alfred Hospital	Melbourne
Australia	Blacktown Hospital	Sydney

Sponsors (2)

Lead Sponsor	Collaborator
AskGene Pharma, Inc.	Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety[DLTs?AEs?ECG]	Incidence of dose limiting toxicities (DLTs); Incidence of adverse events (AEs), laboratory abnormalities, and ECG abnormalities	21days
Secondary	Maximum plasma concentration (Cmax)	To evaluate the systemic pharmacokinetics of ASKG315 in subjects.	21days
Secondary	Area under the concentration time curve (AUC)	To evaluate the systemic pharmacokinetics of ASKG315 in subjects.	21days
Secondary	Cytokine	Changes in circulating cytokine levels.	21days
Secondary	Immunocyte	Changes in immunocyte levels by flow cytometry.	21days